Background: Patients surviving an initial stroke present a significantly increased risk for further strokes. Left atrial appendage closure (LAAC) became an alternative treatment to pharmacological therapy for stroke prevention in atrial fibrillation (AF) patients. Objective: To evaluate the long-term efficacy of LAAC in primary and secondary stroke prevention in patients with AF. Methods: This retrospective study enrolled 139 patients following LAAC who were divided into 2 groups: 37 patients with prior stroke (Stroke Group) and 102 patients without stroke (Control Group). Overall, cumulative follow-up was 530.1 patient-years. Results: Mean CHADS2, CHA2DS2-VASc scores, and HAS-BLED score were higher in patients with prior stroke compared to patients without stroke (3.0 vs. 1.4, p < 0.0001 and 4.6 vs. 2.3, p < 0.0001, 4.0 vs. 2.8, p < 0.0001, respectively). There were no significant differences between other patient factors (sex, heart failure, hypertension, previous stroke/transient ischemic attack, peripheral vascular disease), which may increase the risk of thromboembolism based on the CHA2DS2-VASc score. Average follow-up was 51.3 months in patients with previous stroke and 50 months in patients without previous stroke. Thromboembolic event rate was 0.8 vs. 0.5 (p = 0.72), bleeding event rate was 0 years vs. 1.4 (p = 0.25), and mortality rates were 0.8 vs. 2.1 (p = 0.38) between the Stroke Group and the Control Group. The estimated reductions in thromboembolic and bleeding risks were 89 and 100%, respectively, in Stroke Group, and 91 and 81%, respectively, in Control Group. Conclusion: Patients with prior stroke may be the preferred group for LAAC regardless of the presence or absence of contraindications for anticoagulant therapy.

Keywords:
Left atrial appendage, Left atrial appendage closure, Secondary stroke, Atrial fibrillation, Thrombus
1.
Wyndham CR. Atrial fibrillation: the most common arrhythmia. Tex Heart Inst J. 2000;27(3):257–67.
2.
Steger C, Pratter A, Martinek-Bregel M, Avanzini M, Valentin A, Slany J, et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. Eur Heart J. 2004 Oct;25(19):1734–40.
3.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 Jun;146(12):857–67.
4.
Mohan KM, Wolfe CD, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, Grieve AP. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke. 2011 May;42(5):1489–94.
5.
EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993 Nov;342(8882):1255–62.
6.
Bartus K, Han FT, Bednarek J, Myc J, Kapelak B, Sadowski J, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J Am Coll Cardiol. 2013 Jul;62(2):108–18.
7.
Litwinowicz R, Bartus M, Burysz M, Brzeziński M, Suwalski P, Kapelak B, et al. Long term outcomes after left atrial appendage closure with the LARIAT device-Stroke risk reduction over five years follow-up. PLoS One. 2018 Dec;13(12):e0208710.
8.
Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, et al.; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009 Aug;374(9689):534–42.
9.
Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K, et al.; PROTECT AF Investigators. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation. 2013 Feb;127(6):720–9.
10.
Bartus K, Morelli RL, Szczepanski W, Kapelak B, Sadowski J, Lee RJ. Anatomic analysis of the left atrial appendage after closure with the LARIAT device. Circ Arrhythm Electrophysiol. 2014 Aug;7(4):764–7.
11.
Litwinowicz R, Bartus M, Ceranowicz P, Brzezinski M, Kapelak B, Lakkireddy D, et al. Left atrial appendage occlusion for stroke prevention in diabetes mellitus patients with atrial fibrillation: long-term results. J Diabetes. 2019 Jan;11(1):75–82.
12.
Litwinowicz R, Bartus M, Ceranowicz P, Kapelak B, Lakkireddy D, Bartuś K. Stroke risk reduction after left atrial appendage occlusion in elderly patients with atrial fibrillation: longterm results. Pol Arch Intern Med. 2018 May 30;128(5):327–329.
13.
Nakai T, Lesh MD, Gerstenfeld EP, Virmani R, Jones R, Lee RJ. Percutaneous left atrial appendage occlusion (PLAATO) for preventing cardioembolism: first experience in canine model. Circulation. 2002 May;105(18):2217–22.
14.
Wiebe J, Franke J, Lehn K, Hofmann I, Vaskelyte L, Bertog S, et al. Percutaneous Left Atrial Appendage Closure With the Watchman Device: Long-Term Results Up to 5 Years. JACC Cardiovasc Interv. 2015 Dec;8(15):1915–21.
15.
Tzikas A, Holmes DR Jr, Gafoor S, Ruiz CE, Blomström-Lundqvist C, Diener HC, et al. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. Europace. 2017 Jan;19(1):4–15.
16.
Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol. 2010 Sep;56(11):827–37.
17.
Freixa X, Gafoor S, Regueiro A, Cruz-Gonzalez I, Shakir S, Omran H, et al. Comparison of Efficacy and Safety of Left Atrial Appendage Occlusion in Patients Aged 75 to ≥75 Years. Am J Cardiol. 2016 Jan;117(1):84–90.
18.
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al.; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014 Dec;130(23):2071–104.
19.
Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke. 1994 Feb;25(2):333–7.
20.
Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, et al.; RE-LY study group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY -trial. Lancet Neurol. 2010 Dec;9(12):1157–63.
21.
Litwinowicz R, Konstanty-Kalandyk J, Goralczyk T, Bartus K, Mazur P. Dabigatran level monitoring prior to idarucizumab administration in patients requiring emergent cardiac surgery. J Thromb Thrombolysis. 2018 Jan;45(1):9–12.
22.
Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation. 2011 Feb;123(4):417–24.
23.
Grygier M, Wojakowski W, Smolka G, Demkow M, Wąsek W, Sorysz D, et al. [Left atrial appendage occlusion: consensus document of Association of Cardiovascular Interventions and Heart Rhythm Section of Polish Cardiac Society]. Kardiol Pol. 2018;76(3):677–97.
24.
Reddy VY, Akehurst RL, Armstrong SO, Amorosi SL, Beard SM, Holmes DR Jr. Time to cost-effectiveness following stroke reduction strategies in AF: warfarin versus NOACs versus LAA closure. J Am Coll Cardiol. 2015 Dec;66(24):2728–39.
25.
Litwinowicz R, Bartus M, Kapelak B, Suwalski P, Lakkireddy D, Lee RJ, et al. Reduction in risk of stroke and bleeding after left atrial appendage closure with LARIAT device in patients with increased risk of stroke and bleeding: long term results. Catheter Cardiovasc Interv. 2019 Mar;ccd.28187.
26.
Chen Y, Zhang Y, Huang W, Huang K, Xu B, Su XI. Primary and Secondary Stroke Prevention Using Left Atrial Appendage Closure with Watchman Devices in Atrial Fibrillation Patients: A Single Center Experience from Mainland China. Pacing Clin Electrophysiol. 2017 Jun;40(6):607–14.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.